Keros Therapeutics is filing for an IPO, according to plans made public Monday — a bold move amid the stock market’s historic nose dive. But it may need to be bold: Until a few days ago, the Lexington, Mass.-based company was very nearly out of money.
The company raised $56 million in a recent Series C financing — but it estimates that without that funding, it wouldn’t have lasted more than a few months, according to the prospectus for its initial public offering. The company confidentially filed the paperwork for its offering on Jan. 21.
About the Author Reprints
